查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1386284

人类乳突病毒 (HPV) 疫苗市场报告：2030 年趋势、预测和竞争分析

Human Papillomavirus (HPV) Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

人类乳突病毒 (HPV) 疫苗趋势与预测

到 2030 年，全球人类乳突病毒 (HPV) 疫苗市场预计将达到 103 亿美元，2024 年至 2030 年复合年增长率为 10.4%。该市场的主要驱动因素是人们对人类乳突病毒(HPV)疫苗益处的认识不断提高、HPV感染疾病上升以及政府不断倡议促进人类乳突病毒(HPV)疫苗。全球人类乳突病毒（HPV）疫苗市场未来性广阔，医院、零售药局、政府供应通路都有商机。

人类乳突病毒 (HPV) 疫苗市场洞察

Lucintel 预测，四价疫苗预计将在预测期内实现最高增长，因为四价疫苗因其安全性和有效性特征而被广泛用于 9 至 12 岁的女孩和男孩。

由于人类乳突病毒(HPV)疫苗采用率高以及政府配合措施推广人类乳突病毒(HPV)疫苗接种，预计北美在预测期内将出现最高成长。

本报告回答了 11 个关键问题：

  • Q.1. 细分市场中最有前途和高成长的机会是什么？
  • Q.2.哪个细分市场将以更快的速度成长？为什么？
  • Q.3.您认为哪些地区未来会出现更快的成长？为什么？
  • Q.4. 影响市场动态的主要因素有哪些？市场的主要挑战和商业风险是什么？
  • Q.5. 这个市场的商业风险和竞争威胁是什么？
  • Q.6.这个市场有哪些新趋势？为什么？
  • Q.7.市场客户需求有何改变？
  • Q.8. 该市场有哪些新发展以及哪些公司处于领先地位？
  • Q.9.这个市场的主要企业有哪些？主要企业采取哪些策略配合措施来发展业务？
  • Q.10. 该市场上的竞争产品有哪些？由于材料或产品替代而导致市场占有率下降的威胁有多大？
  • Q.11.过去五年发生了哪些併购事件，对产业产生了哪些影响？

目录

第一章执行摘要

第二章全球人类乳突病毒（HPV）疫苗市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第三章 2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球人类乳突病毒（HPV）疫苗市场趋势（2018-2023）与预测（2024-2030）
  • 全球人类乳突病毒 (HPV) 疫苗市场（按类型）
    • 四价
    • 非价的
    • 二价
  • 按配销通路的全球人类乳突病毒 (HPV) 疫苗市场
    • 医院和零售药房
    • 政府供应商
    • 其他的

第四章 2018-2030年区域市场趋势及预测分析

  • 全球人类乳突病毒（HPV）疫苗市场区域分布
  • 北美人类乳突病毒（HPV）疫苗市场
  • 欧洲人类乳突病毒（HPV）疫苗市场
  • 亚太地区人类乳突病毒（HPV）疫苗市场
  • 其他地区人类乳突病毒（HPV）疫苗市场

第五章竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第六章 成长机会与策略分析

  • 成长机会分析
    • 全球人类乳突病毒 (HPV) 疫苗市场成长机会（按类型）
    • 全球人类乳突病毒 (HPV) 疫苗市场成长机会（按配销通路）
    • 全球人类乳突病毒（HPV）疫苗市场成长机会（按地区）
  • 全球人类乳突病毒（HPV）疫苗市场的新趋势
  • 战略分析
    • 新产品开发
    • 扩大全球人类乳突病毒（HPV）疫苗市场产能
    • 全球人类乳突病毒（HPV）疫苗市场的合併、收购与合资
    • 认证和许可

第七章主要企业概况

  • Johnson & Johnson
  • Xenetic Biosciences
  • AstraZeneca
  • Merck
  • Serum Institute of India
  • Inovio Pharmaceuticals
  • Bharat Biotech
  • Sanofi
  • GlaxoSmithKline
  • Novartis
简介目录

Human Papillomavirus (HPV) Vaccine Trends and Forecast

The future of the global human papillomavirus (HPV) vaccine market looks promising with opportunities in the hospital & retail pharmacy and government supplier channels. The global human papillomavirus (HPV) vaccine market is expected to reach an estimated $10.3 billion by 2030 with a CAGR of 10.4% from 2024 to 2030. The major drivers for this market are increasing awareness of the benefits of HPV vaccination, rising prevalence of HPV infection, and rising government initiatives to promote HPV vaccination.

A more than 150-page report is developed to help in your business decisions.

Human Papillomavirus (HPV) Vaccine by Segment

The study includes a forecast for the global human papillomavirus (HPV) vaccine by type, distribution channel, and region.

Human Papillomavirus (HPV) Vaccine Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • Tetravalent
  • Nonavalent
  • Bivalent

Human Papillomavirus (HPV) Vaccine Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:

  • Hospital & Retail Pharmacies
  • Government Suppliers
  • Others

Human Papillomavirus (HPV) Vaccine Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Human Papillomavirus (HPV) Vaccine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies human papillomavirus (HPV) vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the human papillomavirus (HPV) vaccine companies profiled in this report include-

  • Johnson & Johnson
  • Xenetic Biosciences
  • AstraZeneca
  • Merck
  • Serum Institute Of India
  • Inovio Pharmaceuticals
  • Bharat Biotech
  • Sanofi
  • GlaxoSmithKline
  • Novartis

Human Papillomavirus (HPV) Vaccine Market Insights

Lucintel forecasts that tetravalent is expected to witness highest growth over the forecast period due to its significant usage among girls and boys ages 9 through 12 owing to its features like safety and effectiveness.

North America is expected to witness highest growth over the forecast perioddue to higher adopotion of HPV vaccine and increasing government initiatives to promote HPV vaccination in the region.

Features of the Global Human Papillomavirus (HPV) Vaccine Market

Market Size Estimates: Human papillomavirus (HPV) vaccine market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Human papillomavirus (HPV) vaccine market size by type, distribution channel, and region in terms of value ($B).

Regional Analysis: Human papillomavirus (HPV) vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, distribution channels, and regions for the human papillomavirus (HPV) vaccine market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the human papillomavirus (HPV) vaccine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1 What is the human papillomavirus (HPV) vaccine market size?

Answer: The global human papillomavirus (HPV) vaccine market is expected to reach an estimated $10.3 billion by 2030.

Q.2 What is the growth forecast for human papillomavirus (HPV) vaccine market?

Answer: The global human papillomavirus (HPV) vaccine market is expected to grow with a CAGR of 10.4% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the human papillomavirus (HPV) vaccine market?

Answer: The major drivers for this market are increasing awareness of the benefits of HPV vaccination, rising prevalence of HPV infection, and rising government initiatives to promote HPV vaccination.

Q4. What are the major segments for human papillomavirus (HPV) vaccine market?

Answer: The future of the human papillomavirus (HPV) vaccine market looks promising with opportunities in the hospital & retail pharmacy and government supplier channels.

Q5. Who are the key human papillomavirus (HPV) vaccine market companies?

Answer: Some of the key human papillomavirus (HPV) vaccine companies are as follows:

  • Johnson & Johnson
  • Xenetic Biosciences
  • AstraZeneca
  • Merck
  • Serum Institute Of India
  • Inovio Pharmaceuticals
  • Bharat Biotech
  • Sanofi
  • GlaxoSmithKline
  • Novartis

Q6. Which human papillomavirus (HPV) vaccine market segment will be the largest in future?

Answer: Lucintel forecasts that tetravalent is expected to witness highest growth over the forecast period due to its significant usage among girls and boys ages 9 through 12 owing to its features like safety and effectiveness.

Q7. In human papillomavirus (HPV) vaccine market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness highest growth over the forecast perioddue to higher adopotion of HPV vaccine and increasing government initiatives to promote HPV vaccination in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the human papillomavirus (HPV) vaccine market by type (tetravalent, nonavalent, and bivalent), distribution channel (hospital & retail pharmacies, government suppliers, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Human Papillomavirus (HPV) Vaccine Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Human Papillomavirus (HPV) Vaccine Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Human Papillomavirus (HPV) Vaccine Market by Type
    • 3.3.1: Tetravalent
    • 3.3.2: Nonavalent
    • 3.3.3: Bivalent
  • 3.4: Global Human Papillomavirus (HPV) Vaccine Market by Distribution Channel
    • 3.4.1: Hospital & Retail Pharmacies
    • 3.4.2: Government Suppliers
    • 3.4.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Human Papillomavirus (HPV) Vaccine Market by Region
  • 4.2: North American Human Papillomavirus (HPV) Vaccine Market
    • 4.2.2: North American Human Papillomavirus (HPV) Vaccine Market by Distribution Channel: Hospital & Retail Pharmacies, Government Suppliers, and Others
  • 4.3: European Human Papillomavirus (HPV) Vaccine Market
    • 4.3.1: European Human Papillomavirus (HPV) Vaccine Market by Type: Tetravalent, Nonavalent, and Bivalent
    • 4.3.2: European Human Papillomavirus (HPV) Vaccine Market by Distribution Channel: Hospital & Retail Pharmacies, Government Suppliers, and Others
  • 4.4: APAC Human Papillomavirus (HPV) Vaccine Market
    • 4.4.1: APAC Human Papillomavirus (HPV) Vaccine Market by Type: Tetravalent, Nonavalent, and Bivalent
    • 4.4.2: APAC Human Papillomavirus (HPV) Vaccine Market by Distribution Channel: Hospital & Retail Pharmacies, Government Suppliers, and Others
  • 4.5: ROW Human Papillomavirus (HPV) Vaccine Market
    • 4.5.1: ROW Human Papillomavirus (HPV) Vaccine Market by Type: Tetravalent, Nonavalent, and Bivalent
    • 4.5.2: ROW Human Papillomavirus (HPV) Vaccine Market by Distribution Channel: Hospital & Retail Pharmacies, Government Suppliers, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Human Papillomavirus (HPV) Vaccine Market by Type
    • 6.1.2: Growth Opportunities for the Global Human Papillomavirus (HPV) Vaccine Market by Distribution Channel
    • 6.1.3: Growth Opportunities for the Global Human Papillomavirus (HPV) Vaccine Market by Region
  • 6.2: Emerging Trends in the Global Human Papillomavirus (HPV) Vaccine Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Human Papillomavirus (HPV) Vaccine Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Human Papillomavirus (HPV) Vaccine Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Johnson & Johnson
  • 7.2: Xenetic Biosciences
  • 7.3: AstraZeneca
  • 7.4: Merck
  • 7.5: Serum Institute of India
  • 7.6: Inovio Pharmaceuticals
  • 7.7: Bharat Biotech
  • 7.8: Sanofi
  • 7.9: GlaxoSmithKline
  • 7.10: Novartis